Form 8-K · Current report
Altria 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000764180
- Accession no.
- 0000764180-26-000093
Summary
Altria Group reported 2026 second-quarter and first-half results and narrowed its 2026 full-year adjusted diluted EPS guidance to $5.61–$5.72, a 3.5%–5.5% growth rate from a 2025 base of $5.42, with CEO Sal Mancuso citing smoke-free portfolio progress and shareholder returns.
Key points
- Second-quarter net revenues were essentially unchanged at $6.1 billion, while revenues net of excise taxes rose 1.2% to $5.4 billion.
- Second-quarter adjusted diluted EPS rose 2.8% to $1.48; first-half adjusted diluted EPS rose 4.9% to $2.80.
- Altria returned nearly $3.9 billion to shareholders in the first half through $3.6 billion of dividends and $335 million of share repurchases.
- 2026 capital expenditure guidance was raised to $375–$450 million, from a prior $300–$375 million, mainly for consolidation of USSTC's manufacturing operations.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On July 30, 2026, Altria Group, Inc. (“Altria”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference in this Item 2.02. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.